Zobrazeno 1 - 10
of 286
pro vyhledávání: '"Atazanavir-ritonavir"'
Autor:
Abdulafeez Akinloye, Timothy Oyedeji, Oluwasegun Eniayewu, Babatunde Adeagbo, Oluseye Bolaji, Steve Rannard, Andrew Owen, Adeniyi Olagunju
Publikováno v:
Future Pharmacology, Vol 4, Iss 1, Pp 163-172 (2024)
Nitazoxanide use is limited by gastrointestinal side effects associated with increasing dose. In this drug repurposing study, we investigated the possibility of enhancing the exposure of its active metabolite, tizoxanide, through pharmacokinetic inte
Externí odkaz:
https://doaj.org/article/ad3164d6fda54a9f9f397e6f92216d2e
Autor:
Sikiru Olatunji Usman, Ibrahim Adekunle Oreagba, AbdulWasiu Busari, Akinwumi Akinyede, Ololade Adewumi, Michael Rotimi Kadri, Olayinka Hassan, Yinka Adeyemi Fashina, Esther Oluwatoyin Agbaje, Sulaimon Alani Akanmu
Publikováno v:
Saudi Pharmaceutical Journal, Vol 30, Iss 5, Pp 605-612 (2022)
The interplay of artemether-lumefantrine (AL) and atazanavir-ritonavir (ATVr) with Cytochrome P (CYP) 3A4 isoenzyme and QTc-interval may spawn clinically significant drug interactions when administered concomitantly. Cardiotoxicity and other adverse
Externí odkaz:
https://doaj.org/article/8dae4ffed550432fbfb007f993c5f0e1
Publikováno v:
Caspian Journal of Internal Medicine, Vol 13, Iss Covid 19 Supplement 2, Pp 173-179 (2022)
Background: Evaluation of protease inhibitors (PIs) is important in terms of prescribing an effective regimen for reducing mortality and hospitalization in Covid-19. Therefore, follow-up of patients better determines the characteristics of existing r
Externí odkaz:
https://doaj.org/article/1c27a5bc0ef54e65ba6776be960dd355
Autor:
Adeola Fowotade, Folasade Bamidele, Boluwatife Egbetola, Adeniyi F. Fagbamigbe, Babatunde A. Adeagbo, Bolanle O. Adefuye, Ajibola Olagunoye, Temitope O. Ojo, Akindele O. Adebiyi, Omobolanle I. Olagunju, Olabode T. Ladipo, Abdulafeez Akinloye, Adedeji Onayade, Oluseye O. Bolaji, Steve Rannard, Christian Happi, Andrew Owen, Adeniyi Olagunju
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
BackgroundThe nitazoxanide plus atazanavir/ritonavir for COVID-19 (NACOVID) trial investigated the efficacy and safety of repurposed nitazoxanide combined with atazanavir/ritonavir for COVID-19.MethodsThis is a pilot, randomized, open-label multicent
Externí odkaz:
https://doaj.org/article/6ec8b0e393c14d61b51ccf329a597ef4
Autor:
Adeniyi Olagunju, Adeola Fowotade, Ajibola Olagunoye, Temitope Olumuyiwa Ojo, Bolanle Olufunlola Adefuye, Adeniyi Francis Fagbamigbe, Akindele Olupelumi Adebiyi, Omobolanle Ibitayo Olagunju, Olabode Taiwo Ladipo, Abdulafeez Akinloye, Babatunde Ayodeji Adeagbo, Adedeji Onayade, Oluseye Oladotun Bolaji, Christian Happi, Steve Rannard, Andrew Owen
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-3 (2021)
Abstract Objectives To investigate the efficacy and safety of repurposed antiprotozoal and antiretroviral drugs, nitazoxanide and atazanavir/ritonavir, in shortening the time to clinical improvement and achievement of SARS-CoV-2 polymerase chain reac
Externí odkaz:
https://doaj.org/article/6708633f3a154f358761faaee9a0c1ce
Publikováno v:
Biology, Medicine & Natural Product Chemistry, Vol 8, Iss 2, Pp 47-52 (2019)
Medication use during pregnancy is challenging due to the occurrence of maternal or fetal toxicities. Atazanavir/ritonavir (ATV/r) has hepatotoxic potential hence; use in pregnant patients living with human immunodeficiency virus may cause maternal h
Externí odkaz:
https://doaj.org/article/da27555249f5492082976e0880fc6def
Autor:
Dennis Miyoge Ongubo, Robertino Lim, Hannock Tweya, Christopher Chikhosi Stanley, Petros Tembo, Richard Broadhurst, Salem Gugsa, McNeil Ngongondo, Colin Speight, Tom Heller, Sam Phiri, Mina C. Hosseinipour
Publikováno v:
BMC Infectious Diseases, Vol 17, Iss 1, Pp 1-10 (2017)
Abstract Background Malawi’s national antiretroviral therapy program provides atazanavir/ritonavir–based second line regimens which cause concentration-dependent rise in indirect bilirubin. We sought to determine if elevated bilirubin, as a surro
Externí odkaz:
https://doaj.org/article/b1bb69d1e17f41ae80616f3739f02128
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Mostafa Mohammadi, Malihe Hasannezhad, Anahid Nourian, Hossein Khalili, Morteza Nabiee, Fereshteh Ghiasvand, Mir Saeed Yekaninejad, Sara Ghaderkhani, Arash Seifi, Hamid Rahmani, Effat Davoudi-Monfared, Ladan Abbasian, Setayesh Sadeghi
Publikováno v:
DARU Journal of Pharmaceutical Sciences
Background The role of the antiviral therapy in treatment of COVID-19 is still a matter to be investigated. Also efficacy and safety of antiviral regimens were not compared according severity of the disease. In this study the efficacy and safety of h
Publikováno v:
African Health Sciences
Background: This systematic review and meta-analysis was conducted to evaluate the safety and effectiveness of Atazanavir/ritonavir over lopinavir/ritonavir in human immunodeficiency virus-1 (HIV-1) infection. Methods: Clinical trials with a head-to-